It’s been said that data is the new oil, something pharma researchers understand well. The phrase hits especially close to home for artificial intelligence (AI) researchers who work heavily with medical images. Medical imaging is a powerful diagnostic tool in the drug development process, as it can provide the efficacy and safety monitoring required in…
Why Big Pharma is partnering with startups as it becomes more data-driven
Big Pharma’s ability to innovate has grown in recent years, and the industry’s increasing reliance on data could help it sustain momentum in the future. While McKinsey notes that the industry has been relatively slow in adopting technologies such as AI and automation, the industry is growing more tech-savvy. “The acceptance of data is picking up across…
Digital transformation will give scientists their time back and speed the development pipeline
The pandemic exposed the innovation divide between the digitally transformed and those that lagged. Strict regulation made life sciences and bio/pharma organizations hesitant to modernize too quickly away from proven legacy methods and technologies, resulting in varying levels of digital transformation. But since the pandemic, organizations now recognize the necessity of digitalization and smart automation…
The role of natural language processing in advancing disease research
In any area of disease research, a deep understanding of recent and future trends surrounding a particular condition is crucial to the drug discovery process. But with the volume of scientific literature increasing all the time, it is difficult to manually sift through all the existing information and correlate data in such a way to…
3 ways to reduce implicit bias in predictive analytics for better health equity
The COVID-19 pandemic has brought into sharp focus the racioethnic and socioeconomic disparities inherent in the U.S. healthcare system. These disparities take the form of increased adverse health outcomes and reduced quality of life for affected groups. For example, a study of cities that reported COVID-19 deaths by race and ethnicity found that 34% of…
9 predictions for pharma in 2022
The pharma industry has been slower to embrace technologies such as AI and digital technology than many less-regulated sectors. The COVID-19 pandemic has changed the equation, forcing pharma companies to become more agile and open-minded in approaching drug discovery and development, including managing evolving clinical trials. In this article, several experts offered their predictions of…
How AI technology can democratize clinical trials in oncology
While drug developers continue to develop promising investigational cancer drugs, conducting clinical research in oncology remains difficult. Here’s how AI-enabled software can help. The statistics on inadequate trial recruitment and endemic challenges in oncology clinical trials are well known. They have only gotten worse over the past 20 years. While the number of cancer treatments…
Decentralized clinical trials continue to gain ground
The COVID-19 pandemic has led to fundamental changes in how pharmaceutical companies and physicians interact with patients. And yet — for all of the talk about digital transformation, artificial intelligence (AI) and decentralized clinical trials in medicine in recent years — the adoption of those concepts has lagged. “The reality is that we’ve gone after…
On ePRO and ensuring data integrity
As clinical trials have become more decentralized, there has been an increased focus on the need for more patient-centric drug development. This focus has led to a variety of eClinical applications. Electronic patient-reported outcomes (ePRO) and other electronic clinical outcome assessment (eCOA) approaches can transform trials to make them more pragmatic, patient-centric and efficient. Such…
Q&A: Keys to unlock data science potential for drug discovery
For all of its promise in healthcare and elsewhere, deploying artificial intelligence is frequently a challenging endeavor. “Close collaboration between data science teams, other project team members and stakeholders is essential,” said Jennifer Bradford, director of data science at Phastar, the London-headquartered contract research organization. While input from computational, statistical or medical experts could be…
Researchers at Genuity and Yale shed light on aortic aneurysms
Researchers at privately-held Genuity Science and Yale University Medical School have revealed why aortic aneurysms form. The scientists discovered that an expansion in abnormal cells in smooth muscle tissue of the aorta can contribute to aortic aneurysm. The researchers came to that conclusion by using a combination of generative artificial intelligence, single-cell biology and RNA sequencing to…
Researchers aim to speed drug discovery with human-understandable ML models
Researchers at Purdue University have devised chemical reactivity flowcharts and novel machine learning models that could accelerate drug discovery. Although the use of machine learning for drug development has grown, researchers’ ability to understand machine learning recommendations has been limited. In a paper published in Organic Letters, Purdue professor Gaurav Chopra noted that the machine…
AI VIVO’s artificial intelligence may have found more drugs to fight COVID-19
AI VIVO (Cambridge, UK) says it is looking for pharma and biotech companies interested in working on therapeutic candidates that its artificial intelligence has identified as “top-ranked” for COVID-19. The company says it has found that multiple groups around the world already are conducting clinical trials for 41 of the candidate drugs from its top-ranked…